

Obstetrical Complications Associated With Abnormal Maternal Serum Markers Analytes

This technical update has been reviewed by the Genetics Committee and reviewed and approved by the Executive of the Society of Obstetricians and Gynaecologists of Canada.

PRINCIPAL AUTHORS

Alain Gagnon, MD, Vancouver BC

R. Douglas Wilson (Chair), MD, Philadelphia PA

SOCIETY OF OBSTETRICIANS AND GYNAECOLOGISTS OF CANADA GENETICS COMMITTEE

François Audibert, MD, Montreal QC

Victoria M. Allen, MD, Halifax NS

Claire Blight, RN, Halifax NS

Jo-Ann Brock, MD Halifax NS

Valerie A. Désilets, MD, Montreal QC

Alain Gagnon, MD, Vancouver BC

Jo-Ann Johnson, MD, Calgary AB

Sylvie Langlois, MD, Vancouver BC

Anne Summers, MD, Toronto ON

R. Douglas Wilson (Chair), MD, Philadelphia, PA

Philip Wyatt, MD, Toronto ON

Disclosure statements have been received from all members of the committee.

Evidence: The Cochrane Library and Medline were searched for English-language articles published from 1966 to February 2007, relating to maternal serum markers and perinatal outcomes. Search terms included PAPP-A (pregnancy associated plasma protein A), AFP (alpha-fetoprotein), hCG (human chorionic gonadotropin), estriol, unconjugated estriol, inhibin, inhibin-A, maternal serum screen, triple marker screen, quadruple screen, integrated prenatal screen, first trimester screen, and combined prenatal screen. All study types were reviewed. Randomized controlled trials were considered evidence of the highest quality, followed by cohort studies. Key individual studies on which the recommendations are based are referenced. Supporting data for each recommendation are summarized with evaluative comments and references. The evidence was evaluated using the guidelines developed by the Canadian Task Force on Preventive Health Care.

Values: The evidence collected was reviewed by the Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada.

Benefits, Harms, and Costs: The benefit expected from this guideline is to facilitate early detection of potential adverse pregnancy outcomes when risks are identified at the time of a maternal serum screen. It will help further stratification of risk and provide options for pregnancy management to minimize the impact of pregnancy complications. The potential harms resulting from such practice are associated with the so called false positive (i.e., uncomplicated pregnancies labelled at increased risk for adverse perinatal outcomes), the potential stress associated with such a label, and the investigations performed for surveillance in this situation. No cost-benefit analysis is available to assess costs and savings associated with this guideline.

Summary Statements

1. An unexplained level of a maternal serum marker analyte is defined as an abnormal level after confirmation of gestational age by ultrasound and exclusion of maternal, fetal, or placental causes for the abnormal level. (III)
2. Abnormally elevated levels of serum markers are associated with adverse pregnancy outcomes in twin pregnancies, after correction for the number of fetuses. Spontaneous or planned multifetal reductions may result in abnormal elevations of serum markers. (II-2)

Recommendations

1. In the first trimester, an unexplained low PAPP-A (< 0.4 MoM) and/or a low hCG (< 0.5 MoM) are associated with an increased frequency of adverse obstetrical outcomes, and, at present, no specific protocol for treatment is available. (II-2A) In the second trimester, an unexplained elevation of maternal serum AFP (> 2.5 MoM), hCG (> 3.0 MoM), and/or inhibin-A (\geq 2.0 MoM) or a

Abstract

Objective: To review the obstetrical outcomes associated with abnormally elevated or decreased level of one or more of the most frequently measured maternal serum marker analytes used in screening for aneuploidy. To provide guidance to facilitate the management of pregnancies that have abnormal levels of one of more markers and to assess the usefulness of these markers as a screening test.

Options: Perinatal outcomes associated with abnormal levels of maternal serum markers analytes are compared with the outcomes of pregnancies with normal levels of the same analytes or the general population.

Key Words: Prenatal screening, maternal serum markers, obstetrical complications

This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC.

- decreased level of maternal serum AFP (< 0.25 MoM) and/or unconjugated estriol (< 0.5 MoM) are associated with an increased frequency of adverse obstetrical outcomes, and, at present, no specific protocol for treatment is available. (II-2A)
2. Pregnant woman with an unexplained elevated PAPP-A or hCG in the first trimester and an unexplained low hCG or inhibin-A and an unexplained elevated unconjugated estriol in the second trimester should receive normal antenatal care, as this pattern of analytes is not associated with adverse perinatal outcomes. (II-2A)
 3. The combination of second or third trimester placenta previa and an unexplained elevated maternal serum AFP should increase the index of suspicion for placenta accreta, increta, or percreta. (II-2B) An assessment (ultrasound, MRI) of the placental–uterine interface should be performed. Abnormal invasion should be strongly suspected, and the planning of delivery location and technique should be done accordingly. (III-C)
 4. A prenatal consultation with the medical genetics department is recommended for low unconjugated estriol levels (<0.3 MoM), as this analyte pattern can be associated with genetic conditions. (II-2B)
 5. The clinical management protocol for identification of potential adverse obstetrical outcomes should be guided by one or more abnormal maternal serum marker analyte value rather than the false positive screening results for the trisomy 21 and/or the trisomy 18 screen. (II-2B)
 6. Pregnant woman who are undergoing renal dialysis or who have had a renal transplant should be offered maternal serum screening, but interpretation of the result is difficult as the level of serum hCG is not reliable. (II-2A)
 7. Abnormal maternal uterine artery Doppler in association with elevated maternal serum AFP, hCG, or inhibin-A or decreased PAPP-A identifies a group of women at greater risk of IUGR and gestational hypertension with proteinuria. Uterine artery Doppler measurements may be used in the evaluation of an unexplained abnormal level of either of these markers. (II-2B)
 8. Further research is recommended to identify the best protocol for pregnancy management and surveillance in women identified at increased risk of adverse pregnancy outcomes based on an abnormality of a maternal serum screening analyte. (III-A)
 9. In the absence of evidence supporting any specific surveillance protocol, an obstetrician should be consulted in order to establish a fetal surveillance plan specific to the increased obstetrical risks (maternal and fetal) identified. This plan may include enhanced patient education on signs and symptoms of the most common complications, increased frequency of antenatal visits, increased ultrasound (fetal growth, amniotic fluid levels), and fetal surveillance (biophysical profile, arterial and venous Doppler), and cervical length assessment. (III-A)

10. Limited information suggests that, in women with elevated hCG in the second trimester and/or abnormal uterine artery Doppler (at 22–24 weeks), low-dose aspirin (60–81 mg daily) is associated with higher birthweight and lower incidence of gestational hypertension with proteinuria. This therapy may be used in women who are at risk. (II-2B)
11. Further studies are recommended in order to assess the benefits of low-dose aspirin, low molecular weight heparin, or other therapeutic options in pregnancies determined to be at increased risk on the basis of an abnormal maternal serum screening analyte. (III-A)
12. Multiple maternal serum markers screening should not be used at present as a population-based screening method for adverse pregnancy outcomes (such as preeclampsia, placental abruption, and stillbirth) outside an established research protocol, as sensitivity is low, false positive rates are high, and no management protocol has been shown to clearly improve outcomes. (II-2D)

When maternal serum screening is performed for the usual clinical indication (fetal aneuploidy and/or neural tube defect), abnormal analyte results can be utilized for the identification of pregnancies at risk and to direct their clinical management. (II-2B) Further studies are recommended to determine the optimal screening method for poor maternal and/or perinatal outcomes. (III-A)

J Obstet Gynaecol Can 2008;30(10):918–932

INTRODUCTION

First and second trimester serum screening has been used for many years in Canada as a method of identifying fetuses at increased risk of open neural tube defects and chromosomal abnormalities, in particular trisomy 21 and trisomy 18. The use of maternal serum screening for aneuploidy is described in the “Prenatal Screening for Fetal Aneuploidy Guidelines” published in this journal in February 2007.¹ Over the years, a variety of other pregnancy outcomes have been associated with abnormal values of the different analytes used in these screening tests. The goal of this guideline is to provide a summary of the obstetrical risks associated with values outside the normal range (see definitions below) for the five common first and second trimester serum screening markers: alphafetoprotein, human chorionic gonadotropin, unconjugated estriol, inhibin-A, and pregnancy associated plasma protein-A. Table 2 shows the typical timing of testing for these analytes. This guideline provides guidance for the evaluation and management of these screening variations. Table 3 provides a summary of levels associated with poor obstetrical outcomes in the second trimester.

MATERNAL SERUM ALPHAFETOPROTEIN

Elevated Maternal Serum AFP

Unexplained elevation of maternal serum AFP has been typically defined as a AFP > 2.5 MoM in the absence of fetal chromosomal abnormalities, fetal structural anomalies (e.g., open neural tube defect, abdominal wall defect), placental anomalies such as chorioangioma, multiple

ABBREVIATIONS

AFP	alphafetoprotein
CI	confidence interval
hCG	human chorionic gonadotropin
IUFD	intrauterine fetal demise
IUGR	intrauterine growth restriction
MoM	multiples of the median
ONTD	open neural tube defects
OR	odds ratio
PAPP-A	pregnancy associated plasma protein A
RR	relative risk
uE ₃	unconjugated estriol

Table 1. Key to evidence statements and grading of recommendations, using the ranking of the Canadian Task Force on Preventive Health Care

Quality of Evidence Assessment*	Classification of Recommendations†
I: Evidence obtained from at least one properly randomized controlled trial	A. There is good evidence to recommend the clinical preventive action
II-1: Evidence from well-designed controlled trials without randomization	B. There is fair evidence to recommend the clinical preventive action
II-2: Evidence from well-designed cohort (prospective or retrospective) or case-control studies, preferably from more than one centre or research group	C. The existing evidence is conflicting and does not allow to make a recommendation for or against use of the clinical preventive action; however, other factors may influence decision-making
II-3: Evidence obtained from comparisons between times or places with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of treatment with penicillin in the 1940s) could also be included in this category	D. There is fair evidence to recommend against the clinical preventive action
III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees	E. There is good evidence to recommend against the clinical preventive action
	L. There is insufficient evidence (in quantity or quality) to make a recommendation; however, other factors may influence decision-making

*The quality of evidence reported in these guidelines has been adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on Preventive Health Care.¹⁶²

†Recommendations included in these guidelines have been adapted from the Classification of Recommendations criteria described in the The Canadian Task Force on Preventive Health Care.¹⁶²

pregnancy, or fetal demise or maternal conditions such as ovarian tumour or choriocarcinoma.²

Although the exact cause for an unexplained elevation is not completely understood, placental pathology studies suggest that it is associated with chorionic villitis and placental vascular lesions.³ These lesions allow leakage of the AFP from the high concentration fetal circulation to the low concentration maternal circulation, thereby elevating the maternal serum AFP. It has also been associated with an increased frequency of maternal uterine malformation,⁴ possibly related to abnormal placentation.

Obstetrical Complications

Table 4 provides a summary of the complications that have been described with unexplained elevated maternal serum AFP. This relationship is also present in high-risk groups, such as women with thrombophilias^{5,6} and in cases of fetal echogenic bowel.⁷ The mean maternal serum AFP value is higher in women who develop gestational hypertension with proteinuria and adverse features before 32 weeks' gestation rather than after 32 weeks' gestation.⁸ Higher levels of maternal serum AFP appear to correlate with a higher incidence of poor pregnancy outcome,^{9–12} ranging from 19% at 2.5–2.9 MoM to 70% at ≥ 5.0 MoM.¹¹ An elevation of amniotic fluid AFP in association with an unexplained elevated maternal serum AFP carries a higher risk of preterm delivery (iatrogenic or spontaneous [60%, RR 4.0; 95% CI 2.8–5.7]).¹³ An increased frequency of persistent placenta previa and abnormal placental invasion has been

described in case reports and in case-control and cohort studies in association with maternal serum AFP > 2.0 or 2.5 MoM.^{14–20}

Low Maternal Serum AFP

Low maternal serum AFP, defined as a maternal serum AFP value < 0.25 MoM, has been associated with spontaneous abortion,^{21,22} preterm birth,²² stillbirth,^{22,23} infant death,²² and increased macrosomia.^{24,25}

MATERNAL SERUM HUMAN CHORIONIC GONADOTROPIN

Elevated hCG

Unexplained elevation of second trimester hCG has been defined with cut-offs varying from > 2.0 MoM to > 4.0 MoM in the absence of fetal chromosomal abnormalities, placental anomalies (e.g., molar pregnancy), multiple pregnancy, or fetal demise. Although the exact cause for an unexplained elevation is not completely understood, hypoxic cytotrophoblasts demonstrate increased proliferation and increase hCG production.^{26,27} Case reports have associated elevated hCG with chorioangiomas of the placenta (an abnormal capillary proliferation that has been associated with in utero hypoxia).²⁸ The coexistence of elevated unexplained hCG and confined placental mosaicism has been described.²⁹ Placentas from pregnancies with an elevated hCG were more likely to be large for gestational age and to demonstrate decidual plasma cells and retroplacental hematomas.³⁰

Table 2. Typical timing of testing of different analytes

First trimester (10–14 weeks)	Second trimester (15–21 weeks)
PAPP-A	AFP
hCG	Estriol
	hCG
	Inhibin

Table 3. Summary of level of analytes associated with poor obstetrical outcomes after 24 weeks

	↓	↑
PAPP-A	Yes	No
hCG	Yes in T1	Yes in T2
AFP	Yes	Yes
Estriol	Yes	No
Inhibin	No	Yes

Obstetrical Complications

Table 5 summarizes the complications associated with isolated unexplained elevation of hCG in the second trimester. There appears to be a certain degree of correlation between higher levels of hCG and higher frequency of perinatal complications such as IUGR,^{31–34} gestational hypertension with proteinuria with or without adverse features,^{33,35–37} preterm labour or delivery,^{26,32} and stillbirth.³⁷ The relationship also seems to apply to a population at high risk for gestational hypertension on the basis of previous history.³⁸

In the first trimester, an elevation of hCG has not been associated with a significant increase in pregnancy complications.^{39–42}

Low hCG

Isolated low hCG is usually defined as a value < 0.5 MoM in the context of normal values of the other serum analytes. It is considered “unexplained” when associated with normal fetal anatomy in a viable pregnancy with a normal fetal karyotype. Using these parameters, pregnancy outcomes appear to be similar to those of the general population in the second trimester.^{43–45}

In the first trimester, low levels of hCG (< 0.4 or 0.5 MoM) have been associated with a higher incidence of birthweight below the fifth or tenth centile (OR 1.6–1.7; 95% CI 1.1–2.5)^{46,47} and miscarriage (OR 11.7; 95% CI 6.9–19.8).⁴⁸ Extremely low levels (< 1st centile or < 0.25 MoM) have been associated with an increased risk of spontaneous loss before 24 weeks (adjusted OR range: 3.6–62.0).^{47,48}

MATERNAL SERUM UNCONJUGATED ESTRIOL

Elevated uE₃

High uE₃ has not been associated with adverse perinatal outcomes.

Low uE₃

Low maternal serum uE₃ is defined by most authors as a level ≤ 0.5 MoM.^{49–51} Undetectably low uE₃ is based on the laboratory standard and is typically found in 0.14% of samples.⁵² It has been associated with fetal chromosomal anomalies, fetal structural anomalies (anencephaly), fetal death and a variety of fetal metabolic conditions (e.g., steroid sulfatase deficiency (X-linked ichthyosis), congenital adrenal hypoplasia/hypocortisolism, Smith-Lemli-Opitz syndrome, and placental aromatase deficiency).^{1,53–64} In the majority of these conditions, the level of estriol is reported as undetectable or < 0.2 MoM. Sulfatase deficiency has been associated with prolonged pregnancies and difficulties in inducing labour.⁵⁴ Table 6 provides a summary of complications described with unexplained low level of uE₃. The frequency of these adverse outcomes has an inverse relationship with the uE₃ level.⁶⁵ Two small case series looking at undetectable levels of uE₃ described outcomes similar to those with normal levels, excluding the prolonged pregnancies and increased rates of Caesarean section.^{52,54}

MATERNAL SERUM INHIBIN-A

Inhibin-A is a second trimester marker and is used in the quadruple (quad) screen. Its value is significantly decreased in the presence of primary antiphospholipid antibodies syndrome (median MoM: 0.60 MoM [95% CI 0.4–0.9]).⁶⁶ It has also been described as extremely elevated in pregnancies complicated by triploidy and HELLP syndrome and following the loss of one twin in the first trimester.⁶⁷

Elevated Inhibin-A

Higher levels of inhibin-A are seen in the second trimester in women who subsequently develop gestational hypertension with proteinuria.⁶⁸ No clear cut-off of clinical relevance has been described.⁶⁹ Table 7 summarizes the adverse outcomes associated with unexplained isolated elevated inhibin-A level (≥ 2.0 MoM).

Low Inhibin-A

No adverse obstetrical outcomes have been described with low inhibin-A levels in the second trimester.

MATERNAL SERUM PREGNANCY ASSOCIATED PLASMA PROTEIN-A

PAPP-A is one of the two maternal serum markers currently used for screening between 10 and 14 weeks. It is

Table 4. Complications associated with an unexplained isolated elevation of maternal serum AFP*

Complication	Frequency (range reported, %)	OR or RR (range reported)
Intrauterine growth restriction	10.9–27.1	1.6–4.0
Antepartum hemorrhage (all causes)	12.5	–
Abruption	4–5.6	4.8–11
Preterm delivery	5.8–21.4	1.8–4.8
Fetal death > 24 weeks	3.2–7.2	4.4–9.8
Spontaneous abortion	4.6	3.6–10.1
Gestational hypertension	5.1	1.6–1.9
Gestational hypertension with proteinuria	4.6–13.9	3.8
Infant death	–	1.9
Oligohydramnios	1.2–2.0	3.3
Perinatal morbidity (low Apgar, asphyxia and neonatal intensive care unit admissions)	13.5	–
Spontaneous preterm labour	5.6	3.6

*Only values demonstrating statistical significance were included in this table.

References: 9,11,20,22,23,25,51,73,80,81,116,145,146,149–152. Papers selected if population series > 5000 women or case-control series with > 100 cases.

produced by the placenta and decidua. It increases the bioavailability of insulin-like growth factor, which in turn mediates trophoblast invasion and modulates glucose and amino acids transport in the placenta.

Elevated PAPP-A

No adverse obstetrical outcomes have been described with elevated PAPP-A levels in the first trimester.^{46,47}

Low PAPP-A

Although earlier case-control studies did not report any significant differences in obstetrical outcomes associated with PAPP-A level,⁷⁰ more recent cohort studies describe increased adverse obstetrical outcomes associated with PAPP-A level below the fifth or tenth centile (< 0.4 MoM or 0.5 MoM). Table 8 summarizes the complications associated with unexplained low PAPP-A. The lower PAPP-A levels are associated with higher OR of an adverse outcome.⁴⁷

Summary Statement

1. An unexplained level of a maternal serum marker analyte is defined as an abnormal level after confirmation of gestational age by ultrasound and exclusion of maternal, fetal, or placental causes for the abnormal level. (III)

Recommendations

1. In the first trimester, an unexplained low PAPP-A (< 0.4 MoM) and/or a low hCG (< 0.5 MoM) are associated with an increased frequency of adverse obstetrical

outcomes, and, at present, no specific protocol for treatment is available. (II-2A) In the second trimester, an unexplained elevation of maternal serum AFP (> 2.5 MoM), hCG (> 3.0 MoM), and/or inhibin-A (≥ 2.0 MoM) or a decreased level of maternal serum AFP (< 0.25 MoM) and/or unconjugated estriol (< 0.5 MoM) are associated with an increased frequency of adverse obstetrical outcomes, and, at present, no specific protocol for treatment is available. (II-2A)

2. Pregnant woman with an unexplained elevated PAPP-A or hCG in the first trimester and an unexplained low hCG or inhibin-A and an unexplained elevated unconjugated estriol in the second trimester should receive normal antenatal care, as this pattern of analytes is not associated with adverse perinatal outcomes. (II-2A)
3. The combination of second or third trimester placenta previa and an unexplained elevated maternal serum AFP should increase the index of suspicion for placenta accreta, increta, or percreta. (II-2B) An assessment (ultrasound, MRI) of the placental–uterine interface should be performed. Abnormal invasion should be strongly suspected, and the planning of delivery location and technique should be done accordingly. (III-C)
4. A prenatal consultation with the medical genetics department is recommended for low unconjugated estriol levels (< 0.3 MoM), as this analyte pattern can be associated with genetic conditions. (II-2B)

Table 5. Complications associated with an unexplained isolated elevation of hCG in the second trimester*

Complication	Frequency (range reported, %)	OR or RR (range reported)
Intrauterine growth restriction (< 10th centile or < 3rd centile)	5–15.5	1.5–4.7
Preterm delivery	5.4–11	1.7–2.8
Preterm labour before or at 28 weeks	–	2.74 (1.9–4.8)
Preterm delivery before or at 32 weeks	1.5	–
Spontaneous abortion	1.1–2.5	2.2–4.8
Fetal death > 20 weeks	1.2–5.9	2.7–7.08
Gestational hypertension (overall)	4.1–28	1.4–4.1
Gestational hypertension with proteinuria	1.8–7.4	1.7–6.9
Velamentous cord insertion	3.8	2.6

*Only values demonstrating statistical significance were included in this table.

References: 20,26,31,33,51,80,81,145,152–156. Papers selected if population series > 5000 women or case-control series with > 100 cases.

Table 6. Complications associated with an unexplained isolated low uE₃*

Complication	Frequency (range reported, %)	OR or RR range (95% CI)
Intrauterine growth restriction (birthweight < 10th centile)	4.6–16	1.79–2.89
Fetal death > 24 weeks	2.1	3.3 (2.2–4.9)
Pregnancy loss	1.8–8.4	3.3–7.0
Oligohydramnios	14	3.85 (1.53–9.68)

*Only values demonstrating statistical significance were included in this table. References: 49,51,54

COMBINED ASSESSMENT OF MULTIPLE MARKERS

The combination of multiple abnormal markers and their association with adverse perinatal outcomes has been studied in a variety of ways since the introduction of multiple marker screening. While some authors have described the obstetrical data looking at the screen positive status for trisomy 21, trisomy 18, and ONTD, others have looked at combinations based on the cut-offs described above for isolated unexplained elevations or reductions of the different markers.

Maternal Screen Positive for Trisomy 21

The serum marker pattern leading to a positive screen result represents a variation of one or more of the markers. For example, in the second trimester, a positive screen for trisomy 21 may be associated with an abnormally low maternal serum AFP or uE₃ and/or an abnormally high maternal serum hCG. Overall, in case-control studies, a false positive screen for trisomy 21 has been associated with an increased risk of gestational hypertension with

proteinuria (3.6–6.9%, OR 1.3), small-for-gestational age (5.2%, OR 1.4), and spontaneous fetal loss (1.5–1.7%, OR 1.8).^{71–73} This relationship may not be true for some subpopulations, such as Hispanic women where a small case-control study did not demonstrate any significant differences in obstetrical outcomes.⁷⁴

Maternal Screen Positive for Trisomy 18

Two studies have been published regarding the obstetrical outcome of women who screened positive for trisomy 18 only. A non-statistically significant tendency toward a higher frequency of fetal growth restriction (4.9% vs. 3.3%) and gestational hypertension with proteinuria (2.9% vs. 1.2%) was identified.⁷⁵ In a review of over 250 000 triple markers screening tests performed in Ontario, a false positive risk of trisomy 18 of 1 in 1110 or higher was associated with an overall risk of fetal loss of 14% (2.0% if risk between 1 in 491 and 1 in 1110, 35.7% if risk between 1 in 46 and 1 in 70 and up to 70% if the risk was 1 in 8 or greater).⁷³

Table 7. Complications associated with an unexplained isolated elevation of inhibin A (≥ 2.0 MoM)*

Complication	Frequency (%)	OR or RR (95% CI)
Intrauterine growth restriction	16.9	1.53 (1.27–1.85)
Preterm delivery before or at 32 weeks	3.1	2.38 (1.44–3.95)
Fetal death > 24 weeks	0.9	2.41 (1.04–5.56)
Gestational hypertension with proteinuria	6.63	2.39 (1.75–3.26)

*Only values demonstrating statistical significance were included in this table.

Reference: 51

Table 8. Complications associated with an unexplained isolated low PAPP-A (below the 5th centile [0.4 MoM])*

Complication	Frequency (range reported, %)	OR or RR range (95% CI)
Intrauterine growth restriction (birthweight < 5th centile)	9.3–13.3	2.8 -3.1
Preterm delivery	6.9–10.5	2.2–2.4
Fetal death > 24 weeks	0.9–2	3.9 -9.2
Gestational hypertension (overall)	–	1.47 (1.20–1.82)
Gestational hypertension with proteinuria	6.7–14.1	2.1 (1.6–3.2)
Spontaneous abortion	11.26	2.5 -13.3

*Only values demonstrating statistical significance were included in this table

References: 40,46–48,128, 146,157

Dual Positivity (Maternal Screen Positive for Trisomy 21 and ONTD)

This situation is typically associated with an increase of maternal serum AFP and hCG in the second trimester, leading to the dual positivity. It is seen in about 1 in every 1000 second trimester screens performed.^{76,77} The largest case-control study revealed an association with an increased risk of at least one obstetrical complication (43%, OR 6.0; 95% CI 4.3–8.5). The risk of specific complications were as follows: IUFD: 4.8% (OR 11.8; 95% CI 3.2–52.7), preterm delivery: 23% (OR 5.9; 95% CI 3.8–9.3), gestational hypertension with proteinuria: 15.9% (OR 6.7; 95% CI 3.8–11.6), IUGR: 12.7% (OR 9.7; 95% CI 4.9–19.1) and preterm premature rupture of membranes: 10% (OR 1.8; 95% CI 1.01–3.2).⁷⁶ An association with confined placental mosaicism for trisomy 16 has also been described in up to 30% of these cases.⁷⁸

Dual Positivity (Maternal Screen Positive for Trisomy 21 and Trisomy 18)

In a population of 32 women with a positive triple marker screen for trisomy 21 and trisomy 18, 14 had a fetus with a chromosomal or structural anomaly, eight were lost spontaneously and five had pregnancy complications such as preterm labour and abruption.⁷⁹

Assessment Based on Individual Values of the Markers

Table 9 summarizes the adverse obstetrical outcomes described in association with multiple abnormal maternal serum markers. In general, the tendency for their frequency or odds ratio is increased when more than one abnormal marker is identified.^{20,51,80,81}

Recommendation

5. The clinical management protocol for identification of potential adverse obstetrical outcomes should be guided by one or more abnormal maternal serum marker analyte value rather than the false positive screening results for the trisomy 21 and/or the trisomy 18 screen. (II-2B)

MULTIPLE PREGNANCIES

Although screening for trisomy 21 based on maternal serum is not recommended in multiple pregnancies,⁸² for a variety of reasons (unknown multiple pregnancy at the time of screening, screening for ONTD, maternal choice), many women with multiple pregnancies will have results of maternal serum screening. In twin pregnancies, the value of each analyte appears to be about 1.7–2.1 times the value in a singleton pregnancy.^{83–85} Consequently, abnormal elevation of maternal serum AFP and hCG has been studied at cut-offs of ≥ 3.5 MoM for AFP⁸⁶ and ≥ 5.0 MoM for hCG³³

Table 9. Multiple serum screening anomalies and associated adverse pregnancy outcomes (list of stronger associations than for each marker alone)

↑MSAFP, ↑MShCG	Gestational hypertension, Intrauterine growth restriction (< 10th centile and < 3rd centile), fetal death, medically indicated and spontaneous preterm deliveries, abdominal pregnancy, non-immune hydrops at the time of screening, spontaneous abortion, abruption, absent or reversed end diastolic flow (AREDF) on UA Doppler ^{20,51,80,81, 91,152,158,159}
↑MSAFP, ↑MShCG, ↓MSuE ₃	Low birth weight, ¹⁶⁰ small for gestational age, ¹⁵² spontaneous abortion, ¹⁵² fetal demise after 24 weeks ¹⁵²
↑MSAFP, ↑Inhibin A	Preterm birth ≤ 32 weeks, Intrauterine growth restriction, gestational hypertension with proteinuria, spontaneous abortion, fetal demise ⁵¹
↑MShCG, ↑Inhibin A	Preterm birth ≤ 32 weeks, Intrauterine growth restriction, gestational hypertension with proteinuria, fetal demise ⁵¹
↑MSAFP, ↑MShCG, ↑Inhibin A	Preterm birth ≤ 32 weeks, Intrauterine growth restriction, gestational hypertension with proteinuria, spontaneous abortion, fetal demise ⁵¹
↑MSAFP, ↓MSuE ₃	Small for gestational age, ^{152,161} spontaneous abortion, ¹⁵² fetal demise after 24 weeks ¹⁵²
↑MSAFP, ↓PAPP-A	Small for gestational age, preterm labour and delivery, fetal demise after 24 weeks ¹⁴⁶
↑MShCG, ↓MSuE ₃	Small for gestational age, spontaneous abortion, fetal demise after 24 weeks ¹⁵²

in the second trimester. Unexplained elevation of AFP has been associated with increased preterm deliveries (38% vs. 17%, OR 3.0; 95% CI 1.5–6.2) and increased spontaneous preterm deliveries (31% vs. 16%, OR 2.4; 95% CI 1.1–5.0).⁸⁶ Isolated elevation of hCG in the second trimester has been associated with an increased frequency of preterm deliveries (55% vs. 43%, OR 1.6; 95% CI 1.1–2.6), miscarriages (3% vs. 0.5%, OR 7.1; 95% CI 1.2–31.6), and overall adverse perinatal outcomes (71% vs. 55%, OR 2.0; 95% CI 1.2–3.3).³³

Multifetal Reduction

Transabdominal multifetal reduction performed between 10 and 13 weeks has been associated with significant increases in maternal serum AFP, with a mean AFP varying between 4.6 MoM and 9.3 MoM,^{87–89} although other authors failed to demonstrate such increase.⁹⁰ A spontaneous reduction (“vanishing twin”) within four weeks of testing has been associated with higher levels of PAPP-A and hCG in the first trimester.⁹¹

Summary Statement

2. Abnormally elevated levels of serum markers are associated with adverse pregnancy outcomes in twin pregnancies, after correction for the number of fetuses. Spontaneous or planned multifetal reductions may result in abnormal elevations of serum markers. (II-2)

FACTORS AFFECTING THE LEVELS OF VARIOUS MATERNAL SERUM MARKERS

Maternal factors such as ethnicity, smoking, consanguinity, geographical altitude, and hemoglobin level, as well as fetal gender, have been described as influencing the level of the maternal serum markers. Women who are undergoing renal

dialysis or who have had a renal transplant have significantly higher levels of maternal serum hCG than control groups.^{92,93} Assisted reproductive technologies have been associated with a slight increase in hCG levels.^{94–97} In women infected with HIV, variations in hCG and AFP have been demonstrated and have depended on the viral load, CD4 count, and protease inhibitors intake.^{98,99} Although these differences were statistically significant, they cannot be considered clinically significant in the context of assessment for obstetrical complications of pregnancy.^{100–107} Ethnicity and pre-existing diabetes influence these values^{108–114} and are already taken into account in the standard risk calculations. Diet may be influential, since women on a vegetarian diet who have low levels of vitamin B₁₂ demonstrate higher hCG levels.¹¹⁵ However, at this point, levels of hCG should not be corrected for a vegetarian diet.

Recommendation

6. Pregnant woman who are undergoing renal dialysis or who have had a renal transplant should be offered maternal serum screening, but interpretation of the result is difficult as the level of serum hCG is not reliable. (II-2A)

EVALUATION AND MANAGEMENT OF WOMEN WITH ONE OR MORE ABNORMAL SERUM MARKERS

Evaluation and subsequent patient management need to be based on the potential complications associated with the serum marker pattern and the overall risk associated with this pattern. The more the pattern of abnormalities implies a specific adverse outcome, the more targeted the management will need to be.

Second Trimester Evaluation

The first step in the evaluation process is to confirm that the findings are truly unexplained via history, physical examination, and prenatal ultrasound, as well as invasive prenatal testing when indicated, in order to rule out a cause for the abnormal serum findings. An ultrasound should be performed to confirm the gestational age and exclude common causes of abnormal levels of analytes, such as wrong dating, fetal anomalies, fetal demise, and multiple pregnancy. If the abnormal level remains unexplained, a referral for a detailed anatomical ultrasound should be considered.

1. Detailed ultrasound

In a detailed ultrasound, particular attention should be paid to the placental appearance and location. Three authors have associated the presence of placental pathology on ultrasound (periplacental hemorrhage, intraplacental maternal venous lakes ≥ 1 cm in diameter, thickened placenta, and echogenic cystic lesions) with worse prognosis for these pregnancies.^{116–118} In contrast, Kuo et al. suggested a lower pregnancy complications rate for pregnancies with increased maternal serum AFP when sonolucencies (anechoic focus measuring at least 3 mm without blood flow detected) were noted on ultrasound (44.3% vs. 22.2%, $P = 0.06$).¹¹⁹

2. Doppler assessment

Uterine artery Doppler at 22–24 weeks has been particularly studied in women with abnormal maternal serum marker levels. In the presence of an unexplained elevation of maternal serum AFP, uterine artery notching and/or high resistance index (> 95 th centile or 0.6) were associated with higher rates of gestational hypertension with proteinuria (56–58%) and preterm births (44–45%)^{120,121} or overall adverse outcomes (composite score including gestational hypertension with proteinuria, IUGR, IUFD, and preterm delivery).^{122,123}

In women with elevated hCG (≥ 2.0 – 4.0 MoM) in the second trimester, the finding of unilateral or bilateral uterine artery notching is associated with a 25% to 67% risk of IUGR and/or gestational hypertension with proteinuria.^{124–126}

Alkazaleh et al. described improved positive predictive value when uterine artery Doppler with or without placental ultrasound was added to a combination of elevated serum AFP (> 2.0 MoM) and elevated serum hCG (> 2.5 MoM) in the second trimester.¹¹⁸

When inhibin-A is elevated (> 2.8 MoM) and uterine artery notching is noted in at least one artery, Emine et al. described a 100% positive predictive value and overall

71% sensitivity for preeclampsia in an unselected population of 178 women.¹²⁷

Spencer et al. and Pilalis et al. have published extensively on PAPP-A and uterine artery Doppler as a screening test for adverse pregnancy outcomes, mainly preeclampsia and IUGR. In their populations, the combination of low PAPP-A (< 5 th centile) and abnormal uterine artery Doppler (either increased PI or notching) provided a higher sensitivity (up to 62%) than PAPP-A alone (14–23%) or uterine artery Doppler alone (23–55%).^{40,128,129} In this population of women with abnormal levels of maternal serum marker analytes, umbilical artery Doppler at 18–20 weeks (usual initial assessment) does not help in identifying a higher risk group.¹²²

3. Presence of placenta previa

When placenta previa is present in the context of increased maternal serum AFP (see above), a thorough assessment of the placental bed by ultrasound and/or MRI should be done to identify areas suspicious for abnormal invasion.¹³⁰ This situation should lead to planning for the likelihood of significant blood loss at the time of delivery and discussion about hysterectomy. In addition, planned conservative methods to address this potential obstetrical complication should also be discussed.

Recommendations

3. The combination of second or third trimester placenta previa and an unexplained elevated maternal serum AFP should increase the index of suspicion for placenta accreta, increta, or percreta. (II-2B) An assessment (ultrasound, MRI) of the placental–uterine interface should be performed. Abnormal invasion should be strongly suspected, and the planning of delivery location and technique should be done accordingly. (III-C)
7. Abnormal maternal uterine artery Doppler in association with elevated maternal serum AFP, hCG, or inhibin-A or decreased PAPP-A identifies a group of women at greater risk of IUGR and gestational hypertension with proteinuria. Uterine artery Doppler measurements may be used in the evaluation of an unexplained abnormal level of either of these markers. (II-2B)

Maternal and Fetal Surveillance

There is a paucity of studies assessing the effect of altered pregnancy management on adverse outcomes associated with unexplained abnormal maternal serum markers. In a retrospective study, Huerta-Enochian et al. did not find any benefits in terms of earlier or improved detection of perinatal complications from a heightened surveillance program of 25 women (including twice weekly non-stress test and amniotic fluid index determination) compared with

routine care provided to 88 women (without non-stress test and amniotic fluid index determination unless otherwise indicated).¹³¹ A group at higher risk was identified by repetitively abnormal serial umbilical artery Doppler.^{132–134}

Recommendations

8. Further research is recommended to identify the best protocol for pregnancy management and surveillance in women identified at increased risk of adverse pregnancy outcomes based on an abnormality of a maternal serum screening analyte. (III-A)
9. In the absence of evidence supporting any specific surveillance protocol, an obstetrician should be consulted in order to establish a fetal surveillance plan specific to the increased obstetrical risks (maternal and fetal) identified. This plan may include enhanced patient education on signs and symptoms of the most common complications, increased frequency of antenatal visits, increased ultrasound (fetal growth, amniotic fluid levels), and fetal surveillance (biophysical profile, arterial and venous Doppler), and cervical length assessment. (III-A)

Therapeutic Approaches and Interventions

Low-dose aspirin has been studied in a secondary analysis of a study looking at its influence on birth weight. Newborns of women with a maternal serum hCG ≥ 2.0 MoM in the second trimester who had taken aspirin 60 mg daily starting before 22 weeks' gestation had an average birthweight of $3275\text{g} \pm 412\text{g}$ compared with $2859\text{g} \pm 770\text{g}$ for those born of women with a hCG ≥ 2.0 MoM in the second trimester who had taken a placebo during the same period ($P = 0.02$).¹³⁵ This appeared to be related to higher gestational age at delivery but also to higher birthweight for a specific gestational age. There was no statistically significant difference in the incidence of gestational hypertension with proteinuria between these two groups (0/20 in the aspirin group vs. 3/28 in the placebo group, $P = 0.26$) but the study was not powered to test for this difference.

When uterine artery Doppler has been performed, an anomaly of the Doppler (defined either as an increased resistance index or unilateral or bilateral nearly diastolic notching, depending on the study) likely identifies a group of women who may benefit from low dose aspirin therapy (81 mg daily) if initiated between 17 and 24 weeks. In a meta-analysis including five studies, Coomarasamy et al. described a reduction in the rate of gestational hypertension with proteinuria with an OR of 0.55 (95% CI 0.32–0.95).¹³⁶ The number of women needing to be treated to prevent one case of gestational hypertension with proteinuria was calculated at 16 (95% CI 8–316). No other improvements in outcomes were noted as statistically significant. No maternal adverse outcomes were identified in these studies.

Low molecular weight heparin has been used in a small cohort of six women presenting with abnormal maternal serum hCG and/or AFP in the second trimester, abnormal uterine artery Doppler and placental echogenic cystic placental lesions on ultrasound at 18–26 weeks. All had liveborn infants at 33 to 37 weeks' gestation with birthweights varying from 1000 g to 3200 g. A cohort of 14 women with a similar condition seen at the same centre during the study period was used for comparison. Nine of the 14 women experienced a perinatal death.¹¹⁷

Recommendations

10. Limited information suggests that, in women with elevated hCG in the second trimester and/or abnormal uterine artery Doppler (at 22–24 weeks), low-dose aspirin (60–81 mg daily) is associated with higher birthweight and lower incidence of gestational hypertension with proteinuria. This therapy may be used in women who are at risk. (II-2B)
11. Further studies are recommended in order to assess the benefits of low-dose aspirin, low molecular weight heparin, or other therapeutic options in pregnancies determined to be at increased risk on the basis of an abnormal maternal serum screening analyte. (III-A)

MULTIPLE MARKERS SCREEN AS A SCREENING TEST FOR OBSTETRICAL COMPLICATIONS

Despite the clear associations (summarized above) between abnormal serum marker values and adverse pregnancy outcomes, no study has currently shown that such screening methods are sensitive and specific enough to be used in isolation as a screening test for hypertensive disorders of pregnancy, intrauterine growth restriction, preterm labour, perinatal mortality, and placenta accreta.^{14,22,25,39,40,47,51,125,126,128,129,137–146} Studies have described sensitivities varying from 5% to 43% with false positive rates from 3% to 30%, the highest sensitivities being associated with the highest false positive rates. These values were not significantly modified by the addition of uterine artery Doppler.¹²⁴ The opposite approach may not be true. The addition of inhibin-A to uterine artery Doppler screening for gestational hypertension with proteinuria improved the screening value in a small unselected cohort. Aquilina et al. described a sensitivity of 60% with a false positive rate of 3% and a positive likelihood ratio of 20.8 when uterine artery Doppler and inhibin-A were combined in a screening test for pre-term gestational hypertension with proteinuria.⁶⁹ Spencer reported similar improvements in sensitivity when adding PAPP-A to uterine artery Doppler in a screening program (sensitivity improved from 55% to 62%).⁴⁰ Wald et al. published the only two case-control studies describing a theoretical detection rate of

preeclampsia of 34% to 55% with a 5% screen positive rate.^{147,148}

Recommendation

12. Multiple maternal serum markers screening should not be used at present as a population-based screening method for adverse pregnancy outcomes (such as preeclampsia, placental abruption, and stillbirth) outside an established research protocol, as sensitivity is low, false positive rates are high, and no management protocol has been shown to clearly improve outcomes. (II-2D)

When maternal serum screening is performed for the usual clinical indication (fetal aneuploidy and/or neural tube defect), abnormal analyte results can be utilized for the identification of pregnancies at risk and to direct their clinical management. (II-2B) Further studies are recommended to determine the optimal screening method for poor maternal and/or perinatal outcomes. (III-A)

REFERENCES

1. Summers AM, Langlois S, Wyatt P, Wilson RD; SOGC Genetics Committee, CCMG Prenatal Diagnosis Committee, SOGC Diagnostic Imaging Committee. Prenatal screening for fetal aneuploidy. SOGC Clinical Practice Guideline No.187 J Obstet Gynaecol Can 2007;29(2):146–61.
2. Ollendorff DA, Goldberg JM, Abu-Jawdeh GM, Lurian JR. Markedly elevated maternal serum alpha-fetoprotein associated with a normal fetus and choriocarcinoma of the placenta. Obstet Gynecol 1990;76:494–7.
3. Salafia CM, Silberman L, Herrera NE, Mahoney MJ. Placental pathology at term associated with elevated midtrimester maternal serum alpha-fetoprotein concentration. Am J Obstet Gynecol 1988;158:1064–6.
4. Heinonen S, Ryyänen, Kirkinen P, Saarikoski S. Uterine malformation: a cause of elevated maternal serum alpha-fetoprotein concentrations. Prenat Diagn 1996;16:635–9.
5. Ochshorn Y, Kupfermanc MJ, Eldor A, Wolman I, Lessing JB, Yaron Y. Second-trimester maternal serum alpha-fetoprotein (MSAFP) is elevated in women with adverse pregnancy outcome associated with inherited thrombophilias. Prenat Diagn 2001;21:658–61.
6. Silver RM, Draper ML, Byrne JLB, Ashwood EA, Lyon JL, Branch W. Unexplained elevations of maternal serum alpha-fetoprotein in women with antiphospholipid antibodies: a harbinger of fetal death. Obstet Gynecol 1994;83:150–5.
7. Al-Kouatly HB, Chasen ST, Karam AK, Ahner R, Chervenak FA. Factors associated with fetal demise in fetal echogenic bowel. Am J Obstet Gynecol 2001;185:1039–43.
8. Shenhav S, Gemer O, Sassoon E, Volodarsky M, Peled R, Segal S. Mid-trimester triple test levels in early and late onset severe pre-eclampsia. Prenat Diagn 2002;22:579–82.
9. Cusick W, Rodis JF, Vintzileos AM, Albin SM, McMahon M, Campbell WA. Predicting pregnancy outcome from the degree of maternal serum alpha-fetoprotein elevation. J Reprod Med 1996;41:327–32.
10. Nelson WH, Bensen J, Burton BK. Outcomes in patients with unusually high maternal serum alpha-fetoprotein levels. Am J Obstet Gynecol 1987;157:572–6.
11. Crandall BF, Robinson L, Grau P. Risks associated with an elevated maternal serum alpha-fetoprotein level. Am J Obstet Gynecol 1991;165:581–6.
12. Killam, WMP, Miller RC, Seeds JW. Extremely high maternal serum alpha-fetoprotein levels at second trimester screening. Obstet Gynecol 1991;78:257–61.

13. Wenstrom KD, Owen J, Davis RO, Brumfield CG. Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein. Obstet Gynecol 1996;87:213–6.
14. Hung TH, Shau WY, Hsieh CC, Chiu TH, Hsu JJ, Hsieh TT. Risk factors for placenta accreta. Obstet Gynecol 1999;93(4):545–50.
15. Koster EL, Dashe JS, McIntire DD, Ramus RM. Association of maternal serum alpha-fetoprotein with persistent placenta previa. J Matern Fetal Neonatal Med 2004;16:3–7.
16. Kupfermanc MJ, Tamura RK, Wigton TR, Glassenberg R, Socol ML. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1993;82(2):266–9.
17. McDuffie RS, Harkness L, McVay RM, Haverkamp AD. Midtrimester hemoperitoneum caused by placenta percreta in association with elevated maternal serum alpha-fetoprotein level. Am J Obstet Gynecol 1994;171:565–6.
18. McCool RA, Bombard AT, Bartholomew DA, Calhoun BC. Unexplained positive/elevated maternal serum alpha-fetoprotein associated with placenta increta—a case report. J Reprod Med 1992;37(9):827–8.
19. Zelop C, Nadel A, Frigoletto Jr. FD, Pauker S, MacMillan M, Benacerraf BR. Placenta accreta/percreta/increta: A cause of elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1992;80:693–4.
20. Van Rijn M, Van Der Schouw YT, Hagens AM, Visser GHA, Christiaens GCML. Adverse obstetric outcome in low- and high-risk pregnancies: predictive value of maternal serum screening. Obstet Gynecol 1999;94(6):929–34.
21. Doran TA, Valentine GH, Wong PY, Wielgosz G, Benzie RJ, Soltan HC, et al. Maternal serum alpha-fetoprotein screening: report of a Canadian pilot project. CMAJ 1987;137:285–93.
22. Krause TG, Christens P, Wohlfahrt J, Lei U, Westergaard T, Nørgaard-Pedersen B, et al. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcome. Obstet Gynecol 2001;97:277–82.
23. Burton BK. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol 1988;72:709–13.
24. Baschat AA, Harman CR, Farid G, Chodirker BN, Evans JA. Very low second-trimester maternal serum alpha-fetoprotein: Association with high birth weight. Obstet Gynecol 2002;99:531–6.
25. Kiran TS, Bethel J, Bhal PS. Correlation of abnormal second trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcome. J Obstet Gynecol 2005;25(3):253–6.
26. Lieppman RE, Williams MA, Cheng EY, Resta R, Zingheim R, Hickok DE, et al. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome. Am J Obstet Gynecol 1993;168:1852–7.
27. Fox H. Effect of hypoxia on trophoblast in organ culture. A morphologic and autoradiographic study. Am J Obstet Gynecol 1970;107:1058–64.
28. Stroustrup-Smith A, Huang WY, Wong G, Levine D. Placental chorangiomas associated with markedly elevated maternal chorionic gonadotropin: a case report. J Reprod Med 2003;48:827–30.
29. Morssink LP, Sikkema-Raddatz B, Beekhuis JR, De Wolf BTHM, Mantingh A. Placental mosaicism is associated with unexplained second-trimester elevation of MShCG levels, but not with elevation of MSAFP levels. Prenat Diagn 1996;16:845–51.
30. Liu DF, Dickerman LH, Redline RW. Pathologic findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels. Am J Clin Path 1999;111:209–15.
31. Heinonen S, Ryyänen M, Kirkinen P, Saarikoski S. Elevated midtrimester maternal serum hCG in chromosomally normal pregnancies is associated

- with preeclampsia and velamentous umbilical cord insertion. *Am J Perinatol* 1996;13(7):437-41.
32. Hershkovitz R, Erez O, Sheiner E, Landau D, Mankuta D, Mazor M. Elevated maternal mid-trimester chorionic gonadotropin ≥ 4 MoM is associated with fetal cerebral blood flow redistribution. *Acta Obstet Gynecol Scand* 2003;82:22-7.
 33. Lepage N, Chitayat D, Kingdom J, Huang T. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. *Am J Obstet Gynecol* 2003;188:1354-9.
 34. Benn PA, Horne D, Briganti S, Rodis JF, Clive JM. Elevated second-trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein. *Obstet Gynecol* 1996;87:217-22.
 35. Heikkilä A, Makkonen N, Heinonen S, Kirkinen P. Elevated maternal serum hCG in the second trimester increases prematurity rate and need for neonatal intensive care in primiparous preeclamptic pregnancies. *Hypertens Pregnancy* 2001;20(1):99-106.
 36. Shenhav S, Gemer O, Volodarsky M, Zohav E, Segal S. Midtrimester triple test levels in women with severe preeclampsia and HELLP syndrome. *Acta Obstet Gynecol Scand* 2003;82:912-5.
 37. Walton DL, Norem CT, Schoen EJ, Ray GT, Colby CJ. Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy. *NEJM* 1999;341(27):2033-8.
 38. Hershkovitz R, de Swiet M, Kingdom J. Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler. *Hypertens Pregnancy* 2005;24:273-80.
 39. Kavak ZN, Basgul A, Elter K, Uygur M, Gokaslan, H. The efficacy of first-trimester PAPP-A and free β hCG levels for predicting adverse pregnancy outcome. *J Perinat Med* 2006;34:145-8.
 40. Spencer K, Yu CKH, Cowans NJ, Otiqbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free β -hCG and with second-trimester uterine artery Doppler. *Prenat Diagn* 2005;25:949-53.
 41. Yaron Y, Ochshorn Y, Heifetz S, Lehavi O, Sapir Y, Orr-Urtreger A. First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome. *Fetal Diagn Ther* 2002;17:352-6.
 42. De Leon J, Sifuentes G, Hopkins C, Noble V, Gimpel T, Myles T, et al. Maternal serum free beta-hCG levels in uncomplicated pregnancies at the 10th-15th week of gestation and the development of obstetric complications. *J Reprod Med* 2004;49:89-92.
 43. Endres LK, Krotz S, Grobman WA. Isolated low second trimester maternal serum β -human chorionic gonadotropin is not associated with adverse pregnancy outcome. *Am J Obstet Gynecol* 2003;189:755-77.
 44. Santolaya-Forgas J, Burd LI, Burton BK. Clinical significance of low levels of second-trimester maternal serum human chorionic gonadotropin. *Fetal Diagn Ther* 1994;9:362-6.
 45. Sharony R, Grinshpun-Cohen J, Rabi K, Amiel A, Fejgin M. Low maternal serum concentrations of human chorionic gonadotropin as part of the triple test screening: a follow-up study. *J Matern Fetal Neonatal Med* 2003;13:300-4.
 46. Smith GCS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth. *J Clin Endocrinol Metab* 2002;87:1762-7.
 47. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First trimester maternal serum PAPP-A and free-beta subunit human gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (The FASTER trial). *Am J Obstet Gynecol* 2004;191:1446-51.
 48. Rissanen A, Niemimaa M, Suonpää M, Ryyänen M, Heinonen S. Pregnancy-associated plasma protein A, free human chorionic gonadotropin and nuchal translucency as predictors of miscarriage. *Clin Genet* 2006;69:287-9.
 49. Kowalczyk TD, Cabaniss ML, Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. *Obstet Gynecol* 1998;91:396-400.
 50. Kim SY, Kim SK, Lee JS, Kim IK, Lee K. The prediction of adverse pregnancy outcome using low unconjugated estriol in the second trimester of pregnancy without risk of Down's syndrome. *Yonsei Med J* 2000;41(2):226-9.
 51. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, et al. Quad screen as a predictor of adverse pregnancy outcome. *Obstet Gynecol* 2005;106(2):260-7.
 52. Bradley LA, Canick JA, Palomaki GE, Haddow JE. Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. *Am J Obstet Gynecol* 1997;176:531-5.
 53. Keren DF, Canick JA, Johnson MZ, Schaldenbrand JD, Haning RV, Hackett R. Low maternal serum unconjugated estriol during prenatal screening as an indication of placental steroid sulfatase deficiency and X-linked ichthyosis. Case report. *Am J Clin Pathol* 1995;103:400-3.
 54. Schleifer RA, Bradley LA, Richards DS, Ponting NR. Pregnancy outcome for women with very low levels of maternal serum unconjugated estriol on second-trimester screening. *Am J Obstet Gynecol* 1995;173:1152-6.
 55. Schoen E, Norem C, O'Keefe J, Krieger R, Walton D, To TT. Maternal serum unconjugated estriol as a predictor for Smith-Lemli-Opitz syndrome and other fetal conditions. *Obstet Gynecol* 2003;102:167-72.
 56. Ahmed MN, Killam A, Thompson KH, Qumsiyeh MB. Unconjugated estriol as an indication for prenatal diagnosis of steroid sulfatase deficiency by in situ hybridization. *Obstet Gynecol* 1998;92:687-9.
 57. David M, Israel N, Merksamer R, Bar-Nizan N, Borochowitz Z, Bar-El H, et al. Very low maternal serum unconjugated estriol and prenatal diagnosis of steroid sulfatase deficiency. *Fetal Diagn Ther* 1995;10:76-80.
 58. Kashork CD, Sutton VR, Fonda-Allen JS, Schmidt DE, Likhite ML, Potocki L, et al. Low or absent unconjugated estriol in pregnancy: an indicator for steroid sulfatase deficiency detectable by fluorescence in situ hybridization and biochemical analysis. *Prenat Diagn* 2002;22:1028-32.
 59. Glass IA, Lam RC, Chang T, Roitman E, Shapiro LJ, Shackleton CHL. Steroid sulphatase deficiency is the major cause of extremely low oestriol production at mid-pregnancy: A urinary steroid assay for the discrimination of steroid sulphatase deficiency from other causes. *Prenat Diagn* 1998;18:789-800.
 60. Peter M, Partsch CJ, Dörr HG, Sippell WG. Prenatal diagnosis of congenital adrenal hypoplasia. *Horm Res* 1996;46:41-5.
 61. Zalel Y, Kedar I, Tepper R, Chen R, Drugan A, Fejgin M, et al. Differential diagnosis and management of very low second trimester maternal serum unconjugated estriol levels, with special emphasis on the diagnosis of X-linked ichthyosis. *Obstet Gynecol Surv* 1996;51(3):200-3.
 62. Bradley LA, Palomaki GE, Knight GJ, Haddow JE, Opitz JM, Irons M, et al. Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses. Letter to the Editor. *Am J Med Genet* 1999;82:355-8.
 63. Angle B, Tint GS, Yacoub OA, Clark AL. Atypical case of Smith-Lemli-Opitz syndrome: implications for diagnosis. *Am J Med Genet* 1998;80:322-6.
 64. Bick DP, McCorkle D, Stanley WS, Stern HJ, Staszak P, Berkovitz GD, et al. Prenatal diagnosis of Smith-Lemli-Opitz syndrome in a pregnancy with low maternal serum oestriol and a sex-reversed fetus. *Prenat Diagn* 1999;91:68-71.

65. Santolaya-Forgas J, Jessup J, Burd LI, Prins GS, Burton BK. Pregnancy outcome in women with low midtrimester maternal serum unconjugated oestriol. *J Reprod Med* 1996;41:87–90.
66. Maymon R, Sehmi IK, Herman A, Jones RG, Sherman D, Cuckle H. Serum inhibin A levels in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome. *Prenat Diagn* 2000;20:12–6.
67. Goodwin KM, Sweeney PJ, Lambert-Messerlian GM, Canick JA. High maternal serum inhibin A levels following the loss of one fetus in a twin pregnancy. *Prenat Diagn* 2000;20:1015–7.
68. Kim SY, Ryu HM, Yang JH, Kim MY, Ahn HK, Shin JS, et al. Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia. *J Korean Med Sci* 2006;21:452–6.
69. Aquilina J, Thompson O, Thilaganathan B, Harrington K. Improved early prediction of pre-eclampsia by combining second-trimester maternal serum inhibin-A and uterine artery Doppler. *Ultrasound Obstet Gynecol* 2001;17:477–84.
70. Morssink LP, Kornman LH, Hallahan TW, Kloosterman MD, Beekhuis JR, De Wolf BTHM, et al. Maternal serum levels of free β -hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. *Prenat Diagn* 1998;18:147–52.
71. Summers A, Huang T, Meier C, Wyatt PR. The implications of a false positive second-trimester serum screen for Down syndrome. *Obstet Gynecol* 2003;101:1301–6.
72. Pergament E, Stein AK, Fiddler M, Cho NH, Kupferminc MJ. Adverse pregnancy outcome after a false positive screen for Down syndrome using multiple markers. *Obstet Gynecol* 1995;86:255–8.
73. Huang T, Owolabi T, Summers AM, Meier C, Wyatt PR. The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening. *Am J Obstet Gynecol* 2005;193:395–403.
74. Naylor CS, Porto M, Cohen B, Garite TJ. Pregnancy outcome in Hispanic patients with unexplained positive triple marker screening for Down syndrome. *J Matern Fetal Med* 2001;10:20–2.
75. Wenstrom KD, Owen J, Brumfield CG, Davis RO, Dubard M, Garcia T. Significance of a false-positive trisomy 18 multiple-marker screening test. *Obstet Gynecol* 1997;90:938–42.
76. Chitayat D, Farrell SA, Huang T, Meier C, Wyatt PR, Summers AM. Double-positive maternal serum screening results for Down syndrome and open neural tube defects: an indicator for fetal structural or chromosomal abnormalities and adverse obstetric outcomes. *Am J Obstet Gynecol* 2002;187:758–63.
77. Zanini R, Tarantini M, Cerri V, Jacobello C, Bellotti D, Lancetti S, et al. ‘Dual positivity’ for neural tube defects and Down syndrome at maternal serum screening: Gestational outcome. *Fetal Diagn Ther* 1998;13:106–10.
78. Zimmerman R, Lauper U, Streicher A, Huch R, Huch A. Elevated alpha-fetoprotein and human chorionic gonadotropin as a marker for placental trisomy 16 in the second trimester? *Prenat Diagn* 1995;15:1121–4.
79. Summers AM, Huang T, Wyatt PR. Pregnancy outcomes of women with positive serum screening results for Down syndrome and trisomy 18. Letter to the Editor. *Prenat Diagn* 2002;22:266–71.
80. Chandra S, Scott H, Dodds L, Watts C, Blight C, Van den Hof M. Unexplained elevated maternal serum α -fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. *Am J Obstet Gynecol* 2003;189(3):775–81.
81. Morssink LP, Kornman LH, Beekhuis JR, De Wolf BTHM, Mantingh A. Abnormal levels of maternal serum human chorionic gonadotropin and alpha-fetoprotein in the second trimester: relation to fetal weight and preterm delivery. *Prenat Diagn* 1995;15:1041–6.
82. Barrett J, Bocking A. The SOGC consensus statement: management of twin pregnancy. SOGC Consensus Statement No.,91, July 2000. *J Soc Obstet Gynaecol Can* 2000;22(7):519–29.
83. Watt HC, Wald NJ, George L. Maternal serum inhibin-A levels in twin pregnancies: Implications for screening for Down’s syndrome. *Prenat Diagn* 1996;16:927–9.
84. Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. *Prenat Diagn* 1996;16:29–34.
85. Wald N, Cuckle H, Wu T, George L. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in twin pregnancies: implications for screening for Down’s syndrome. *Br J Obstet Gynaecol* 1991;98:905–8.
86. Hong S, Berkowitz G, Wang W, Stone J, Aimbender E. Unexplained elevated maternal serum alpha-fetoprotein levels and pregnancy outcome in twins. *Obstet Gynecol* 1996;88:337–42.
87. Rotmensch S, Celentano C, Shalev J, Vishne TH, Lipitz S, Ben-Rafael Z, et al. Midtrimester maternal serum screening after multifetal pregnancy reduction in pregnancies conceived by in vitro fertilization. *J Assist Reprod Genet* 1999;16(1):8–12.
88. Shulman LP, Phillips OP, Cervetti TA. Maternal serum analyte after first-trimester multifetal pregnancy reduction. *Am J Obstet Gynecol* 1996;174(3):1072–4.
89. Grau P, Robinson L, Tabsh K, Crandall BF. Elevated maternal serum alpha-fetoprotein and amniotic fluid alpha-fetoprotein after multifetal pregnancy reduction. *Obstet Gynecol* 1990;76:1042–5.
90. Groutz A, Amit A, Yaron Y, Yovel I, Wolman I, Legum C, et al. Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction. *Prenat Diagn* 1996;16:723–7.
91. Chasen ST, Perni SC, Predanic M, Kalish RB, Chervenak FA. Does a “vanishing twin” affect first-trimester biochemistry in Down syndrome risk assessment? *Am J Obstet Gynecol* 2006;195:236–9.
92. Karidas CN, Michailidis GD, Spencer K, Economides DL. Biochemical screening for Down syndrome in pregnancies following renal transplantation. *Prenat Diagn* 2002;22:226–30.
93. Cheng PJ, Liu CM, Change SD, Lin YT, Soong YK. Elevated second-trimester maternal serum hCG in patients undergoing haemodialysis. *Prenat Diagn* 1999;19:955–8.
94. Hui PW, Tang MHY, Lam YH, Ng EHY, Yeung WSB, Ho PC. Maternal serum hCG and alpha-fetoprotein levels in pregnancies conceived after IVF or ICSI with fresh and frozen-thawed embryos. *Hum Reprod* 2003;18(3):572–5.
95. Maymon R, Shulman A. Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVG pregnancies. *Hum Reprod* 2001;16(4):691–5.
96. Rätty R, Virtanen A, Koskinen P, Anttila L, Forsström J, Laitinen P, et al. Serum free β -hCG and alpha-fetoprotein levels in ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down’s syndrome. *Hum Reprod* 2002;17(2):481–4.
97. Frishman GN, Canick JA, Hogan JW, Hackett RJ, Kellner LH, Saller DN. Serum triple-marker screening in vitro fertilization and naturally conceived pregnancies. *Obstet Gynecol* 1997;90:98–101.
98. Gross S, Castillo W, Crane M, Espinosa B, Carter S, DeVeaux R, et al. Maternal serum α -fetoprotein and human chorionic gonadotropin levels in women with human immunodeficiency virus. *Am J Obstet Gynecol* 2003;188:1052–6.
99. Einstein FH, Wright RL, Trentacoste S, Gross S, Merkatz IR, Bernstein PS. The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive. *Am J Obstet Gynecol* 2004;191:1004–8.

100. Ghidini A, Spong CY, Grier RE, Walker CN, Pezzullo JC. Is maternal serum triple screening a better predictor of Down syndrome in female than in male fetuses? *Prenat Diagn* 1998;18:123–6.
101. Spong CY, Ghidini A, Stanley-Christian H, Meck JM, Seydel FD, Pezzullo JC. Risk of abnormal triple screen for Down syndrome is significantly higher in patients with female fetuses. *Prenat Diagn* 1999;19:337–9.
102. Rudnicka AR, Wald NJ, Huttly W, Hackshaw AK. Influence of maternal smoking on the birth prevalence of Down syndrome and on second trimester screening performance. *Prenat Diagn* 2002;22:893–7.
103. Spencer K. The influence of fetal sex in screening for Down syndrome in the second trimester using AFP and free β -hCG. *Prenat Diagn* 2000;20:648–51.
104. Khan NR, Saeed M, Cuckle HS. Maternal serum screening maker levels in consanguineous couples. Letter to the Editor. *Prenat Diagn* 2001;21:1175–9.
105. Nuttall KL, Lenke RR, Ashwood ER. Maternal serum α -fetoprotein and altitude. *Med Hypotheses* 2000;54(3):498–500.
106. Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ, Haddow JE, et al. The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. *Br J Obstet Gynaecol* 1990;97:272–6.
107. Bartha JL, Omar KM, Soothill PW. The relationship between maternal serum alpha-fetoprotein and maternal haemoglobin. *Prenat Diagn* 2004;24:609–12.
108. Huttly W, Rudnicka A, Wald NJ. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependant diabetes mellitus. *Prenat Diagn* 2004;24:804–7.
109. Wald NJ, Watt HC, George L. Maternal serum inhibin-a in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. *Prenat Diagn* 1996;16:923–6.
110. Sancken U, Bartels I. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)? *Prenat Diagn* 2001;21:383–6.
111. Wald NJ, Cuckle HS, Densem JW, Stone RB. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. *Br J Obstet Gynaecol* 1992;99:51–3.
112. Bazzett LB, Yaron Y, O'Brien JE, Critchfield G, Kramer RL, Ayoub M, et al. Fetal gender impact on multiple-marker screening results. *Am J Med Genet* 1998;76:369–71.
113. Benn PA, Clive JM, Collins R. Medians for second-trimester maternal serum α -fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. *Clin Chem* 1997;43(2):333–7.
114. Simpson JL, Eliás S, Morgan CD, Shulman L, Umstot E, Andersen RN. Second trimester maternal serum human chorionic gonadotropin and unconjugated oestriol in blacks and whites. Letter to the Editor. *Lancet* 1990;335:1459–60.
115. Cheng PJ, Chu DC, Chueh HY, See LC, Chang HC, Weng DRH. Elevated maternal midtrimester serum free β -human chorionic gonadotropin levels in vegetarian pregnancies that cause increased false-positive Down syndrome screening results. *Am J Obstet Gynecol* 2004;190:442–7.
116. Williams MA, Hickok DE, Zingheim RW, Luthy DA, Kimelman J, Nyberg DA, et al. Elevated maternal serum α -fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. *Am J Obstet Gynecol* 1992;167:1032–7.
117. Alkazaleh F, Viero S, Simchen M, Walker M, Smith G, Laskin C, et al. Ultrasound diagnosis of severe thrombotic placental damage in the second trimester: an observational study. *Ultrasound Obstet Gynecol* 2004;23(5):472–6.
118. Alkazaleh F, Chaddha V, Viero S, Malik A, Anastasiades C, Sroka H, et al. Second-trimester prediction of severe placental complications in women with combined elevations in alpha-fetoprotein and human chorionic gonadotrophin. *Am J Obstet Gynecol* 2006;194:821–7.
119. Kuo PL, Lin CC, Lin YH, Guo HR. Placental sonolucency and pregnancy outcome in women with elevated second trimester serum alpha-fetoprotein levels. *J Formos Med Assoc* 2003;102(5):319–25.
120. Konchak PS, Bernstein IM, Capeless EL. Uterine artery Doppler velocimetry in the detection of adverse obstetric outcomes in women with unexplained elevated maternal serum α -fetoprotein levels. *Am J Obstet Gynecol* 1995;173:1115–9.
121. Chung JE, Cho JS, Han SS, Park YW, Kim JW. Uterine artery Doppler velocimetry in the prediction of adverse obstetric outcomes in unexplained MSAFP elevations. *Yonsei Med J* 2000;41(1):17–21.
122. Bromley B, Frigoletto Jr FD, Harlow BL, Pauker S, Benacerraf BR. The role of Doppler velocimetry in the structurally normal second-trimester fetus with elevated levels of maternal serum α -fetoprotein. *Ultrasound Obstet Gynecol* 1994;4:377–80.
123. Palacio M, Jauniaux E, Kingdom J, Dell E, Sheldrake A, Rodeck CH. Perinatal outcome in pregnancies with a positive serum screening for Down's syndrome due to elevated levels of free β -human chorionic gonadotropin. *Ultrasound Obstet Gynecol* 1999;13:58–62.
124. Audibert F, Benchimol Y, Benattar C, Champagne C, Frydman R. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. *Fetal Diagn Ther* 2005;20:48–53.
125. Barkehall-Thomas A, Wilson C, Baker L, Bhuinain M, Wallace EM. Uterine artery Doppler velocimetry for the detection of adverse obstetric outcomes in patients with elevated mid-trimester β -human chorionic gonadotrophin. *Acta Obstet Gynecol Scand* 2005;84:743–7.
126. Elsandabese D, Srinivas M, Kodakkattil S. The clinical value of combining maternal serum screening and uterine artery Doppler in prediction of adverse pregnancy outcome. *J Obstet Gynaecol* 2006;26(2):115–7.
127. Emine AY, Kavak ZN, Elter K, Gokaslan H, Pekin T. Screening for pre-eclampsia by using maternal serum inhibin A, activin A, human chorionic gonadotropin, unconjugated estriol, and alpha-fetoprotein levels and uterine artery Doppler in the second trimester of pregnancy. *Aust NZ J Obstet Gynaecol* 2005;45:283–8.
128. Pilalis A, Souka AP, Antsaklis P, Daskalakis G, Papanoniou N, Mesogitis S, et al. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11–14 weeks' gestation. *Ultrasound Obstet Gynecol* 2007;29:135–40.
129. Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H. First-trimester maternal serum PP-13, PAPP-A and second trimester uterine artery Doppler pulsatility as markers of pre-eclampsia. *Ultrasound Obstet Gynecol* 2007;29:128–34.
130. Warshak CR, Eskander R, Hull AD, Scioscia AL, Mattrey RF, Benirschke K, et al. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. *Obstet Gynecol* 2006 Sep;108(3 Pt 1):573–81
131. Huerta-Enochian G, Katz V, Erfurth S. The association of abnormal α -fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome? *Am J Obstet Gynecol* 2001;184:1549–55.
132. Wilkins-Haug L. Unexplained elevated maternal serum α -fetoprotein: what is the appropriate follow-up? *Curr Opin Obstet Gynecol* 1998;10:469–74.
133. Jaffa A, Yaron Y, Har-Toov J, Amster R, Legum C, Lessing JB. Doppler velocimetry of the umbilical artery as a predictor of pregnancy outcome in

- pregnancies characterized by elevated maternal serum alpha-fetoprotein and normal amniotic fluid alpha-fetoprotein. *Fetal Diagn Ther* 1997;12:85–8.
134. Yaron Y, Jaffa AJ, Har-Toov J, Lavi H, Legum C, Evans MI. Doppler velocimetry of the umbilical artery as a predictor of outcome in pregnancies characterized by elevated beta-subunit human chorionic gonadotropin. *Fetal Diagn Ther* 1997;12:353–5.
 135. Wenstrom KD, Hauth JC, Goldenberg RL, DuBard MB, Lea C. The effect of low-dose aspirin on pregnancies complicated by elevated human chorionic gonadotropin levels. *Am J Obstet Gynecol* 1995;173:1292–6.
 136. Coomarasamy A, Papaioannou S, Gee H, Khan KS. Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. *Obstet Gynecol* 2001;98:861–6.
 137. Chard T, Rice A, Kitau, MJ, Hird V, Grudzinskas JG, Nysenbaum AM. Mid-trimester levels of alphafetoprotein in the screening of low birthweight. *Br J Obstet Gynaecol* 1986;93:36–8.
 138. Miyakoshi K, Tanaka M, Gabionza D, Ishimoto H, Miyazaki T, Yoshimura Y. Prediction of smallness for gestational age by maternal serum human chorionic gonadotropin levels and by uterine artery Doppler. *Fetal Diagn Ther* 2001;16:42–6.
 139. Ashour AMN, Lieberman ES, Wilkins Haug LE, Repke JT. The value of elevated second-trimester β -human chorionic gonadotropin in predicting development of preeclampsia. *Am J Obstet Gynecol* 1997;176(2):438–42.
 140. Luckas M, Hawe J, Meekins J, Neilson J, Walkinshaw S. Second trimester serum free β human chorionic gonadotropin levels as a predictor of pre-eclampsia. *Acta Obstet Gynecol Scand* 1998;77:381–4.
 141. Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? *Am J Obstet Gynecol* 2000;182(3):589–94.
 142. Butler EL, Dashe JS, Ramus RM. Association between maternal serum alpha-fetoprotein and adverse outcomes in pregnancies with placenta previa. *Obstet Gynecol* 2001;97(1):35–8.
 143. Leung TN, Chung TKH, Madsen G, Lam CWK, Lam PKW, Walters WAW, et al. Analysis of mid-trimester corticotrophin-releasing hormone and α -fetoprotein concentrations for predicting pre-eclampsia. *Hum Reprod* 2000;15(8):1813–8.
 144. Aquilina J, Maplethorpe R, Ellis P, Harrington K. Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotropin for the prediction of pre-eclampsia. *Placenta* 2000;21:487–92.
 145. Smith GCS, Shah I, White IR, Pell JP, Crossley JA, Dobbie R. Maternal and biochemical predictors of spontaneous preterm birth among nulliparous women: a systematic analysis in relation to the degree of prematurity. *Int J Epidemiol* 2006;35:1169–77.
 146. Smith GCS, Shah I, Crossley JA, Aitken DA, Pell JP, Nelson SM, et al. Pregnancy-associated plasma protein A and Alpha-fetoprotein and prediction of adverse perinatal outcome. *Obstet Gynecol* 2006;107(1):161–6.
 147. Wald NJ, Morris JK. Multiple marker second trimester serum screening for pre-eclampsia. *J Med Screen* 2001;8:65–8.
 148. Wald N, Morris JK, Ibbison J, Wu T, George LM. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. *Prenat Diagn* 2006;26:559–64.
 149. Akinbiyi AA. Unexplained elevated maternal serum alpha-fetoprotein in singleton pregnancies as a predictor of fetal risk. *Int J Gynaecol Obstet* 1996;53:17–21.
 150. Davis RO, Goldenberg RL, Boots L, Hoffman JH, Copper R, Cutter GR, et al. Elevated levels of midtrimester maternal serum α -fetoprotein are associated with preterm delivery but not with fetal growth retardation. *Am J Obstet Gynecol* 1992;167:596–601.
 151. Spencer K. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. *Prenat Diagn* 2000;20:652–6.
 152. Yaron Y, Cherry M, Kramer RL, O'Brien JE, Hallak M, Johnson MP, et al. Second trimester maternal serum marker screening: Maternal serum α -fetoprotein, β -human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. *Am J Obstet Gynecol* 1999;181(4):968–74.
 153. Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M. The association between unexplained second trimester maternal serum hCG elevation and pregnancy complications. *Obstet Gynecol* 1992;80(1):83–6.
 154. Fejgin MD, Kedar I, Amiel A, Ben-Tovim B, Chen R, Petel Y, et al. Elevated hCG as an isolated finding during the second trimester biochemical screen: genetic, ultrasonic, and perinatal significance. *Prenat Diagn* 1997;17(11):1027–31.
 155. Towner D, Ghandhi S, El Kady D. Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin. *Am J Obstet Gynecol* 2006;194:1676–82.
 156. Sorensen TK, Williams MA, Zingheim RW, Clement SJ, Hickok DE. Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. *Am J Obstet Gynecol* 1993;169:834–8.
 157. Smith GCS, Crossley JA, Aitken DA, Pell JP, Cameron AD, Connor JM, et al. First-trimester placentation and the risk of antepartum stillbirth. *Obstet Gynecol Surv* 2005;60(4):211–2.
 158. Kuller JA, Sellati LE, Chescheir NC, Helwick JJ, Lincoln-Boyea B, Boor-Smith C, et al. Outcome of pregnancies with elevation of both maternal serum alpha-fetoprotein and human chorionic gonadotropin. *Am J Perinatol* 1995;12(2):93–7.
 159. Saller DN, Canick JA, Oyer CE. The detection of non-immune hydrops through second-trimester maternal serum screening. *Prenat Diagn* 1996;16:431–5.
 160. Milunsky A, Nebiolo L. Maternal serum triple analyte screening and adverse pregnancy outcome. *Fetal Diagn Ther* 1996;11:249–53.
 161. Benn PA, Craffey A, Horne D, Ramsdell L, Rodis JF. Elevated maternal serum alpha-fetoprotein with low unconjugated estriol and the risk for lethal perinatal outcome. *J Matern Fetal Med* 2000;9:165–9.
 162. Woolf SH, Battista RN, Angerson GM, Logan AG, Eel W. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. *CMAJ* 2003;169(3):207–8.